comparemela.com

Latest Breaking News On - Unicycive therapeutics daily - Page 1 : comparemela.com

Unicycive Therapeutics' (UNCY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Wednesday, Benzinga reports. The brokerage currently has a $4.50 price objective on the stock. Several other brokerages have also recently commented on UNCY. Noble Financial started coverage on Unicycive Therapeutics in a research report on […]

United-states
Piper-sandler
Unicycive-therapeutics-company-profile
Vivo-capital
Virtu-financial
Rosalind-advisors-inc
Unicycive-therapeutics-inc
Unicycive-therapeutics
Free-report
Get-free-report
Unicycive-therapeutics-daily

HC Wainwright Reiterates "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $4.50 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 437.76% from the stock’s previous close. A number of […]

United-states
Piper-sandler
Vivo-capital
Nasdaq
Virtu-financial
Rosalind-advisors-inc
Unicycive-therapeutics-inc
Unicycive-therapeutics-company-profile
Unicycive-therapeutics
Get-free-report
Noble-financial
Unicycive-therapeutics-daily

Unicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $4.50 price target on the stock. HC Wainwright’s price objective points to a potential upside of 437.76% from the […]

United-states
Piper-sandler
Virtu-financial
Vivo-capital
Unicycive-therapeutics-inc
Rosalind-advisors-inc
Unicycive-therapeutics
Get-free-report
Unicycive-therapeutics-daily

HC Wainwright Reiterates Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)

HC Wainwright Reiterates Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Piper-sandler
Vivo-capital
Rosalind-advisors-inc
Unicycive-therapeutics-inc
Unicycive-therapeutics
Get-free-report
Noble-financial
Therapeutics-stock-down
Rosalind-advisors
Unicycive-therapeutics-daily

Piper Sandler Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY)

Piper Sandler assumed coverage on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report published on Thursday, Marketbeat.com reports. The brokerage issued an overweight rating and a $9.00 target price on the stock. Other equities research analysts also recently issued research reports about the company. Noble Financial initiated coverage on Unicycive Therapeutics in […]

United-states
Piper-sandler
Unicycive-therapeutics-inc
Goldman-sachs-group-inc
Geode-capital-management
Vivo-capital
Unicycive-therapeutics
Free-report
Therapeutics-trading-down
Get-free-report
Sachs-group
Capital-management

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.